**Patient Information**

**DOB:**
Gender:
Phone:
Patient ID:

**AGE:**

**Specimen Information**

Specimen:
Requisition:
Lab Ref #:
Collected:
Received:
Reported:

**Client Information**

**COMMENTS:**

FASTING: NO

<table>
<thead>
<tr>
<th>Test Name</th>
<th>In Range</th>
<th>Out Of Range</th>
<th>Reference Range</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>CANDIDA ALBICANS AB (IGG, IGA, IGM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. ALBICANS IGG</td>
<td></td>
<td>1.2 H</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. ALBICANS IGA</td>
<td>0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. ALBICANS IGM</td>
<td>0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REFERENCE RANGE: <1.0

**INTERPRETIVE CRITERIA:**

- <1.0 = Antibody Not Detected
- or = 1.0 = Antibody Detected

Systemic candidiasis is often characterized by markedly elevated levels of IgG, IgA, and IgM recognizing Candida. However, interpretation of Candida antibody results is complicated by antibody detection in approximately 40% of healthy individuals and up to 70% of patients positive for other fungal antibodies. Further, antibody responses may be blunted in immunocompromised patients at risk for systemic candidiasis. Candida antibody levels should be considered within the context of clinical findings and results from other relevant laboratory tests, such as Candida antigen detection and/or culture.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

**PERFORMING SITE:**